Menu
Search
|

Menu

Close
X

Syndax Pharmaceuticals Inc SNDX.OQ (NASDAQ Stock Exchange Global Select Market)

7.68 USD
-0.10 (-1.29%)
As of Jun 22
chart
Previous Close 7.78
Open 7.85
Volume 325,581
3m Avg Volume 102,148
Today’s High 7.85
Today’s Low 7.55
52 Week High 15.20
52 Week Low 7.36
Shares Outstanding (mil) 22.22
Market Capitalization (mil) 270.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
2
FY16
1
FY15
1
EPS (USD)
FY18
-0.792
FY17
-2.886
FY16
-2.773
FY15
-5.977
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
221.84
5.71
Price to Book (MRQ)
vs sector
2.48
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
0.00
16.46
LT Debt to Equity (MRQ)
vs sector
0.00
12.19
Return on Investment (TTM)
vs sector
-42.86
14.38
Return on Equity (TTM)
vs sector
-48.61
16.08

EXECUTIVE LEADERSHIP

Dennis Podlesak
Independent Chairman of the Board, Since 2008
Salary: --
Bonus: --
Michael Metzger
President, Chief Operating Officer, Since 2015
Salary: $296,538.00
Bonus: $50,000.00
Briggs Morrison
Chief Executive Officer, Director, Since 2015
Salary: $263,784.00
Bonus: $109,635.00
Richard Shea
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer, Since 2017
Salary: --
Bonus: --
Michael Meyers
Senior Vice President, Chief Development Officer, Since 2015
Salary: $140,625.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Building D, 35 Gatehouse Dr Fl 3
WALTHAM   MA   02451-1215

Phone: +1781.4191400

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

SPONSORED STORIES